Nuwellis, Inc. (NUWE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67113Y7022
Nuwellis, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 8.27 m USD |
| Gross profit | 5.12 m USD |
| Operating income | -11.11 m USD |
| EBIT | -17.52 m USD |
| Net income | -17.52 m USD |
| Diluted EPS – continuing operations | -25.39 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nuwellis, Inc.
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
More stocks
- OFA Group (OFAL)
- KALA BIO, Inc. (KALA)
- Quantum Genesis AI Corp. (QGAI)
- My City Builders, Inc. (MYCB)
- Dror Ortho-Design, Inc. (DROR)
- GBT Technologies Inc. (GTCH)
- CV Sciences, Inc. (CVSI)
- PSQ Holdings, Inc. (PSQH)
- BioNexus Gene Lab Corp (BGLC)
- Iveda Solutions, Inc. (IVDA)
- ADAMANT DRI PROCESSING & MINERALS GROUP (ADMG)
- RELIABILITY INC (RLBY)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.